Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...
Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints
Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
Why Novo Nordisk’s Stock Plunge Rattled Markets Today
Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...
STAT2d
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...
Health Officials Investigating Possible Link Between Ozempic and Eye-Rotting Condition
Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains ...